Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-03
K
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Kenzie B. MacNicol's research investigates the molecular mechanisms underlying translational regulation, with a specific focus on the roles of ELAV-like proteins (ELAVL1 and ELAVL4) in this process. Their work has explored the requirement of these proteins for Musashi-dependent translational activation. Earlier research also examined the potential of parthenolide and melampagnolide-B derivatives as anticancer agents, investigating their effects on cell cycle progression. MacNicol's publication record includes work on xenopus proteins and nerve tissue proteins, suggesting a broad interest in protein function and its biological consequences. Their h-index is 1, with 3 total publications and 21 citations.
Metrics
- h-index: 1
- Publications: 4
- Citations: 21
Selected Publications
-
ELAVL1 and ELAVL4 Are Required for Musashi-Dependent Translational Activation (2026)
-
ELAVL1 and ELAVL4 are required for Musashi-dependent translational activation (2026)
-
Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression (2014)
Collaboration Network
Top Collaborators
Angus M. MacNicol
University of Arkansas for Medical Sciences
3 shared publications
In database
- Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression
- ELAVL1 and ELAVL4 are required for Musashi-dependent translational activation
- ELAVL1 and ELAVL4 Are Required for Musashi-Dependent Translational Activation
Linda Hardy
University of Arkansas for Medical Sciences
2 shared publications
In database
- Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression
- ELAVL1 and ELAVL4 are required for Musashi-dependent translational activation
Katherine Bronson
University of Arkansas for Medical Sciences
2 shared publications
In database
- ELAVL1 and ELAVL4 are required for Musashi-dependent translational activation
- ELAVL1 and ELAVL4 Are Required for Musashi-Dependent Translational Activation
Milla M Reddick
University of Arkansas for Medical Sciences
2 shared publications
In database
- ELAVL1 and ELAVL4 are required for Musashi-dependent translational activation
- ELAVL1 and ELAVL4 Are Required for Musashi-Dependent Translational Activation
Angela K. Odle
University of Arkansas for Medical Sciences
2 shared publications
In database
- ELAVL1 and ELAVL4 are required for Musashi-dependent translational activation
- ELAVL1 and ELAVL4 Are Required for Musashi-Dependent Translational Activation
Gwen V. Childs
University of Arkansas for Medical Sciences
2 shared publications
In database
- ELAVL1 and ELAVL4 are required for Musashi-dependent translational activation
- ELAVL1 and ELAVL4 Are Required for Musashi-Dependent Translational Activation
Melanie C MacNicol
University of Arkansas for Medical Sciences
2 shared publications
In database
- ELAVL1 and ELAVL4 are required for Musashi-dependent translational activation
- ELAVL1 and ELAVL4 Are Required for Musashi-Dependent Translational Activation
Narsimha Reddy Penthala
University of Arkansas for Medical Sciences
1 shared publication
In database
- Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression
Shobanbabu Bommagani
University of Arkansas for Medical Sciences
1 shared publication
In database
- Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression
Venumadhav Janganati
University of Arkansas for Medical Sciences (US)
1 shared publication
- Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression
Chad E. Cragle
University of Arkansas for Medical Sciences (US)
1 shared publication
- Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression
Nikhil Reddy Madadi
University of Arkansas for Medical Sciences (US)
1 shared publication
- Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression
Peter A. Crooks
University of Arkansas for Medical Sciences
1 shared publication
In database
- Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression
Cole R. Bolen
University of Arkansas for Medical Sciences
1 shared publication
In database
- ELAVL1 and ELAVL4 are required for Musashi-dependent translational activation
Alex Lagasse
University of Arkansas for Medical Sciences
1 shared publication
In database
- ELAVL1 and ELAVL4 are required for Musashi-dependent translational activation
Similar Researchers
Based on overlapping research topics
Katherine Bronson
University of Arkansas for Medical Sciences
RNA and protein synthesis mechanisms
Protein Structure and Dynamics
Animal, Disease Models
Dylan Girodat
University of Arkansas at Fayetteville
RNA and protein synthesis mechanisms
Protein Structure and Dynamics
Medical Research
Collis R. Geren
University of Arkansas at Fayetteville
Protein Structure and Dynamics
Animal, Disease Models
Medical Research
Angus M. MacNicol
University of Arkansas for Medical Sciences
RNA and protein synthesis mechanisms
Animal, Disease Models
Medical Research
Milla M Reddick
University of Arkansas for Medical Sciences
RNA and protein synthesis mechanisms
Animal, Disease Models
Medical Research
Sudip Panday
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Protein Structure and Dynamics
Medical Research